AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01590745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS Therasonic 460 Primo Ultrasound therapy
Description: 1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
Study NCT01590745 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EMS Therasonic 460 Primo Ultrasound therapy
Description: 1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
Study NCT00833027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin 100 mg/day - tablet for 24 weeks
Study NCT02116842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine
Description: Epidural block in early labour.
Study NCT02116842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.075% bupivacaine
Description: Epidural block in early labour.
Study NCT02116842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 µg fentanyl
Description: Given with different doses of bupivacaine in epidural block.
Study NCT00876252 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43
Study NCT00876252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl
Study NCT02288000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Study NCT02288000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Study NCT01445613 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RX Acculink Carotid Stent System (RX Acculink)
Description: Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
Study NCT02911142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
Study NCT02911142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: During cycle 1, rituximab will be administered on day 4 prior to the start of EPOCH. During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
Study NCT02911142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: During cycle 1, Prednisone 60 mg/m2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m2 /day PO days 1-5.
Study NCT02911142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etopside
Description: During cycle 1, Etoposide 50 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m2/day continuous intravenous infusion days 1 to 4.
Study NCT02911142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
Study NCT02911142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: During cycle 1, Vincristine 0.4 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
Study NCT02911142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
Study NCT00640991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glulisine insulin, glargine insulin
Description: IV infusion of glulisine, SC injection of glargine
Study NCT01929343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine following cue-induced craving
Description: as described in Arm Description
Study NCT01929343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine following neutral stimulus
Description: as described in Arm Description
Study NCT01929343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: as described in Arm Description
Study NCT06055010 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
Study NCT04576910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccinated with Sabin IPV
Description: the 4th dose of polio vaccination
Study NCT04576910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccinated with bOPV
Description: the 4th dose of polio vaccination
Study NCT01970228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-citrate and 18F-FDG PET/CT imaging
Description: Single-day study of the two PET tracers
Study NCT04406207 — intervention group
Intervention type: OTHER
Intervention: Demonstration of T cell responses
Description: Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest.
Study NCT04306562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition supplement
Description: enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day for at least 14 days from a preanesthetic clinic visit to a day of surgery.
Study NCT02351011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 x 10^6 MSCs
Description: Autologous, bone-marrow derived MSCs
Study NCT02351011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 x 10^6 MSCs
Description: Autologous, bone-marrow derived MSCs
Study NCT02351011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 x 10^6 MSCs
Description: Autologous, bone-marrow derived MSCs
Study NCT01062698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase (rt-PA)/Actilyse
Description: Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
Study NCT01062698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)
Description: Mechanic thrombectomy
Study NCT02567799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Suspension
Description: Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
Study NCT02567799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart.
Study NCT01072331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513
Description: MP-513 10 mg, once a day, for 4 weeks
Study NCT01072331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513
Description: MP-513 20 mg, once a day, for 4 weeks
Study NCT01072331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MP-513
Description: MP-513 placebo, once a day, for 4 weeks
Study NCT04257981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulator v3.0
Description: Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
Study NCT04257981 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control group
Description: The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
Study NCT04608305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 high-dose (prime)
Description: Single administration of IIBR-100 1\*10E7 pfu/ml
Study NCT04608305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 low-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
Study NCT04608305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo
Study NCT04608305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart
Study NCT02567799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart.
Study NCT02018783 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cocorico
Description: Digital application for 60 seconds
Study NCT02567799 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
Study NCT00364650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: 2 capsules twice daily
Study NCT00364650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04545879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raw garlic juice containing allicin
Description: Fresh garlic juice containing around 48mg allicin for 7 days
Study NCT04170998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: Participants receive Evogliptin 5mg orally once a day
Study NCT04170998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evogliptin Placebo
Description: Participants receive placebo to match Evogliptin 5mg orally once a day
Study NCT04170998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Participants receive Dapagliflozin orally once a day
Study NCT04170998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Participants receive Dapagliflozin orally once a day
Study NCT04170998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ≥ 1000mg
Description: Metformin are administered at the same dose and formulation.
Study NCT04170998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin ≥ 1000mg
Description: Metformin are administered at the same dose and formulation.
Study NCT01148901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
Study NCT02270281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine 0.7 Mcg/kg/h
Description: CIF 0.7mcg/kg/h
Study NCT01881282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carraghenates Cream
Description: Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
Study NCT01881282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mayinglong Musk Hemorrhoid Ointment
Description: Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
Study NCT01237431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500ml water intake
Description: subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
Study NCT01237431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500ml water intake
Description: subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
Study NCT02530476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.
Study NCT03379376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Receive questionnaire
Study NCT03379376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Undergo eHealth mindful moving and breathing
Study NCT00735761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-609
Description: Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
Study NCT00735761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir in ME-609 vehicle (5% acyclovir)
Description: Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
Study NCT02399904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: california tri-pull taping
Description: To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
Study NCT01012349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)
Description: 1 tablet in an episody of headache
Study NCT01012349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin - Bayer
Description: 1 tablet in an episody of headache (Aspirin 500mg)
Study NCT04694183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, intravenous drip administration, d1, every 3 weeks.
Study NCT04694183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Oral, d1-14, every 3 weeks.
Study NCT04694183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
Study NCT04694183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
Study NCT03712839 — intervention group
Intervention type: OTHER
Intervention: Cognitive-functional evaluation
Description: The participants will be evaluated with a set of tools within the context of meaningful ADL.
Study NCT00653952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAELYX
Description: Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
Study NCT00653952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel HCl
Description: Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
Study NCT04343326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perform corneal collagen cross linking accelerated and delivery of systemic oxygen
Description: CXL is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
Study NCT04343326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perform corneal collagen cross linking accelerated and without additional oxygen therapy
Description: corneal collagen cross linking with accelerated protocol without additional oxygen therapy
Study NCT04343326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perform Conventiona corneal collagen cross linking
Description: Conventional CXL using 30 mW/CM2 UV-A ablation for 30 minutes
Study NCT01074762 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Structured personal care
Description: General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
Study NCT00580216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux sodium
Description: Pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection
Study NCT00580216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration
Study NCT00580216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for idrabiotaparinux)
Description: Matching pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection
Study NCT01816256 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Upper gastrointestinal endoscopy and Doppler ultrasound
Description: This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
Study NCT03099980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
Study NCT00580216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for warfarin)
Description: Warfarin matching capsules~Oral administration
Study NCT00580216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avidin
Description: Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes
Study NCT00580216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for avidin)
Description: Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes
Study NCT00912483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heparin sodium - Blausiegel
Description: Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
Study NCT00912483 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium - APP
Description: Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
Study NCT03743740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercise
Description: The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.